Waldenström’s Macroglobulinemia (eBook)

Véronique Leblond, Professor in Hematology, is the head of the department of Hematology at Pitié Salpêtrière Hospital, Paris, France. She is the chair of the “French Cooperative Group on Chronic Lymphocytic Leukemia and Waldenström’s Macroglobulinemia: FCG CLL-WM” including more than 90 centers in France and Belgium. She is responsible for a rare tumor network (K-VIROGREF) dedicated to the management of transplant recipients with virus-induced tumors and funded by the French national Institute for cancer in 2012. The team historically focuses on chronic B-cell lymphoproliferative disorders, amyloidosis, on ocular and CNS lymphoma and on lymphoproliferations in immunosuppressed patients (HIV, organ-transplanted patients). She is the head of GRECHY, affiliated to the PhD school ED394 “Physiology & Physio-pathology”. Steven Treon is the Director of the Bing Center for Waldenström’s Research and an attending physician for medical oncology, at Dana-Farber Cancer Institute and Brigham and Women’s Hospital, in Boston, Massachusetts. He is also an Associate Professor of Medicine at Harvard Medical School in Boston, and is the Chair of the Waldenström's Macroglobulinemia Clinical Trials Group. Dr Treon’s main research interests focus on understanding the genetic basis and pathogenesis of Waldenström’s macroglobulinemia and the development of therapeutics for this malignancy. Meletios A. Dimopoulos, MD is Professor and Chairman of the Department of Clinical Therapeutics at the University Athens School of Medicine, Athens, Greece. He is a member of numerous scientific societies and has authored more than 650 publications (April 2013) in peer-reviewed journals. Dr. Dimopoulos serves on the Scientific Advisory Boards of the Multiple Myeloma Research Foundation, of the International Myeloma Foundation, of the International Waldenstrom’s Macroglobulinemia Foundation and he is a member of the Board of the European Myeloma Network.

Preface: Tribute to J WaldenströmPart I: Tumor Cells and microenvironment1. Waldenström Macroglobulinaemia: Pathological Features and Diagnostic Assessment2. Waldenström’s Macroglobulinemia Immunophenotype3. Predispositions and Origins of Waldenstrom Macroglobulinemia: Implications from Genetic Analysis4. Cytogenetics in Waldenström Macroglobulinemia (WM)5. Genetic and Signaling Abnormalities in Waldenström’s Macroglobulinemia6. Molecular Pathways in Growth and Survival: Epigenomics7. The Bone Marrow Microenvironment and Tumor Cells Interactions in Waldenström’s Macroglobulinemia8. Waldenström’s Macroglobulinaemia: Immunosurveillance and the Immune Micro-environmentPart II: Epidemiology and Genetic Predisposition9. Epidemiology of Waldenström Macroglobulinemia10. Genetic Predisposition to Waldenström Macroglobulinemia11. Immunoglobulin Type M Monoclonal Gammopathy of Undetermined Significance (IgM-MGUS)Part III Clinical Features12. Hyperviscosity Syndrome, Cold Agglutinin Hemolytic Anemia, and Cryoglobulinemia13. Neuropathy in Waldenström’s Macroglobulinaemia14. IgM Amyloidosis15. The Bing-Neel Syndrome16. Unusual Manifestations of IgM Monoclonal GammopathiesPart IV: Laboratory Investigations17. Laboratory Investigations and Findings: Hematological Abnormalities, Biochemical Investigations, Free Light and Heavy ChainsPart V: Response18. Response Assessment in Waldenström’s MacroglobulinaemiaPart VI: Prognostic Factors19. Risk Stratification in Waldenström MacroglobulinemiaPart VII: Treatment Options and Recommendations20. Indications for Treatment of Waldenström’s Macroglobulinemia21. Immunotherapy in Waldenström’s Macroglobulinemia22. Immunomodulatory Agents and Proteasome Inhibitors in Waldenström’s Macroglobulinemia23. Signal Inhibitors in Waldenström’s Macroglobulinemia24. High-Dose Therapy and Haemopoietic Stem Cell Transplantation in Waldenström’s Macroglobulinaemia25. Long-Term Toxicity of Therapy in Waldenström Macroglobulinemia26. Treatment Recommendations in Waldenström Macroglobulinemia